By analyzing the proteomes of the brain and cerebrospinal fluid after stroke using high-throughput techniques, researchers have identified several candidate biomarkers that can be used for stroke management and may also serve as targets for treatment, such as the glial fibrillary acidic protein (GFAP) and retinol-binding protein 4 (RBP 4). Here, RBP4 is linked to stroke disorder.